Table 4.
Multivariate Cox regression analyses to identify predictors of biochemical recurrence
| Variables | HR | 95 % CI | P-value | |
|---|---|---|---|---|
| Lower | Upper | |||
| All patients | ||||
| Age | 1.008 | .979 | 1.038 | .604 |
| Preoperative PSA | 1.005 | 1.000 | 1.009 | .042 |
| Post-operative GS (≤7 vs. ≥8) | 1.264 | .822 | 1.943 | .286 |
| Pathologic stage (T2 vs. T3) | .931 | .584 | 1.484 | .763 |
| Margin status (Negative vs. Positive) | 1.159 | .745 | 1.803 | .514 |
| Pelvic and PAFP LN metastasis status | ||||
| Group 1 | 1 | - | - | - |
| Group 2 | 1.335 | .821 | 2.169 | .244 |
| Group 3 | 1.288 | .639 | 2.594 | .479 |
| Patients without adjuvant therapy | ||||
| Age | 1.020 | .985 | 1.055 | .265 |
| Preoperative PSA | 1.003 | .996 | 1.009 | .423 |
| Post-operative GS (≤7 vs. ≥8) | 1.094 | .648 | 1.848 | .737 |
| Pathologic stage (T2 vs. T3) | 1.024 | .601 | 1.746 | .930 |
| Margin status (Negative vs. Positive) | 1.094 | .648 | 1.848 | .555 |
| Pelvic and PAFP LN metastasis status | ||||
| Group 1 | 1 | - | - | - |
| Group 2 | 1.350 | .754 | 2.418 | .312 |
| Group 3 | 1.064 | .406 | 2.792 | .899 |
| Patients with adjuvant therapy | ||||
| Age | .994 | .933 | 1.059 | .842 |
| Preoperative PSA | 1.009 | 1.001 | 1.016 | .019 |
| Post-operative GS (≤7 vs. ≥8) | 1.925 | .774 | 4.788 | .159 |
| Pathologic stage (T2 vs. T3) | .727 | .250 | 2.117 | .559 |
| Margin status (Negative vs. Positive) | 1.316 | .467 | 3.711 | .604 |
| Pelvic and PAFP LN metastasis status | ||||
| Group 1 | 1 | - | - | - |
| Group 2 | 1.633 | .600 | 4.446 | .337 |
| Group 3 | 2.592 | .857 | 7.842 | .092 |
HR, hazard ratio; CI, confidence interval; Group 1, Pelvic LN metastasis only; Group 2, PAFP LN metastasis only; Group 3, Both pelvic LN & PAFP LN metastasis